The Bayer Science and Education Foundation announced Markus Bender as the second winner of the Bayer Thrombosis Reseach Award of 30,000 EUR. Bender showed that the severe blood clotting and immune system disorders in patients suffering from this condition are attributable to a deficiency of the cytoskeleton-stabilizing protein profilin-1 in the precursor cells of blood platelets. This could open up new opportunities for the early detection and treatment of this severe illness in future.
The Thrombosis Research Award has honored aspiring up-and-coming researchers for outstanding achievements in the field of pure and clinical research into thrombosis since 2013. It was established in 2011 by the Bayer scientists Dr. Frank Misselwitz, Dr. Dagmar Kubitza and Dr. Elizabeth Perzborn, who won the German Future Prize in 2009 for developing the anticoagulant Xarelto®.
Said Dr. Frank Misselwitz, prize sponsor and Head of the Cardiovascular and Coagulation Therapeutic Area in Bayer’s Clinical Research, “Markus Bender is a talented researcher whose work stands out from that of the many other nominees. It combines pure research at the molecular level of cytoskeleton stabilization in blood cells with key clinical issues at the interface of coagulation and immunology, and comes to surprising and fundamentally significant conclusions. In view of his outstanding scientific work, Dr. Bender is most particularly deserving of this award.”